About Ken Keller

Chairman of the board , President and CEO of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business. Honored to work alongside thousands of US and global colleagues dedicated to our company’s mission of contributing to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group, focused on the development of oncology therapies and specialty medicines. Proud to lead the transformation of the company into a leader in oncology therapeutics. Dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.

More than 30 years of experience in the pharmaceutical industry in general management including commercial, international and joint venture leadership, as well as serving as Chief Operating Officer in several therapeutic areas, including oncology, rheumatology, dermatology and primary care. Currently serves on the Board of Directors of Daiichi Sankyo, Inc.